Coherus Oncology, Inc.

NASDAQ:CHRS

Biotechnology

Healthcare
$0.41 +1.80%

+$0.03 today

Market cap
$63.35M
Beta
0.96
P/E (TTM)
-1.3
EPS (TTM)
-$1.11
52W Low $0.71High $2.62

Volume 2.55M

Average 1.15M

CHRS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Coherus Oncology, Inc.NASDAQ: CHRS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 136.4M shares rose 17.7% year over year, ahead of the +6.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 13.3% from the prior quarter. Over 3 fiscal years it compounded at +15.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +17.7% holds above the trailing-twelve-month pace of +6.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
136.4M+13.3% QoQ
Last fiscal yearDec 2025
120.37M+5.1% YoY
LTMMar 2026
122.27M+6.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+17.7%——
1 year+5.1%——
3-year CAGR+15.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
120.37M USD
Year-over-year change
+5.1%
4-year CAGR
+12.4%

Weighted Avg Shares vs competitors

How CHRS compares with its peers on the latest reported figures

  • CHRS's LTM Mar 2026 weighted avg shares of 122.27M shares is the 4th highest of the 11 companies compared; the peer median is 92.9M shares.
  • Its year-over-year change of +6.0% is the lowest of 11, against a peer median of +54.8%.
  • Over three fiscal years its annual growth of +15.7% compares with a peer median of +20.6%.
CHRS Competitors Peer median
Weighted Avg Shares for CHRS and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +96.8%+77.8%
CHRSCoherus Oncology, Inc.LTM Mar 2026122.27M +6.0%+15.7%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
PLXProtalix BioTherapeutics, Inc.LTM Mar 202679.09M +6.5%+17.5%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 202615.86M +130.2%+599.3%
Peer median (excluding CHRS) 92.9M+54.8%+20.6%

Competitors are the stored peer set for CHRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue326.55M211.04M257.24M266.96M42.17M
Cost of Revenue57.59M70.08M158.99M117.55M17.74M
Gross Profit268.96M140.96M98.25M149.41M24.43M
Gross Margin82.4%66.8%38.2%56.0%57.9%
Research & Development363.11M199.36M109.44M93.34M104.96M
Selling, General & Admin169.71M198.48M185.62M150.44M99M
Operating Expenses532.82M397.84M301.45M261.07M203.97M
Depreciation & Amortization3.45M3.7M3.79M5.28M3.92M
EBITDA(260.69M)(255.58M)(193.94M)60.94M(170.2M)
EBITDA Margin-79.8%-121.1%-75.4%22.8%-403.6%
Operating Income(263.86M)(256.88M)(203.2M)(111.67M)(179.53M)
Operating Margin-80.8%-121.7%-79.0%-41.8%-425.7%
Interest Income00000
Interest Expense22.96M32.47M40.54M27.16M9M
Other Income / Expenses(23.24M)(34.87M)(35.07M)140.17M(3.59M)
Income Before Tax(287.1M)(291.75M)(238.27M)28.51M(183.12M)
Pre-Tax Margin-87.9%-138.2%-92.6%10.7%-434.2%
Income Tax Expense00(380K)00
Net Income(287.1M)(291.75M)(237.89M)28.51M(170.29M)
Net Margin-87.9%-138.2%-92.5%10.7%-403.8%
EPS (Basic)(3.81)(3.76)(2.53)0.25(1.45)
EPS (Diluted)(3.81)(3.76)(2.53)0.25(1.45)
Weighted Avg Shares75.45M77.63M94.16M114.55M120.37M
Weighted Avg Shares (Diluted)75.45M77.63M94.16M114.83M120.37M

Coherus Oncology, Inc.

NASDAQ:CHRS

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.